Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Private label firm names Mark Olesnavage exec VP and chief operating officer for OTC drug operations. Most recently VP-sales and marketing, Olesnavage takes on additional responsibility for R&D, quality control and human resources and will continue to oversee the development of "new products to maximize on the many" Rx-to-OTC switch opportunities, Perrigo said July 19.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning